The Medulloblastoma Initiative (MBI) was established in 2021 to materialize the vision shared by Brazilian entrepreneur Fernando Goldsztein and Dr. Roger J. Packer. The MBI raises private resources that are channeled to the research on Group 4 medulloblastoma developed by the Cure Group 4 Consortium — which includes 16 laboratories installed in the US, Canada, and Germany. Medulloblastoma is the most common pediatric brain cancer. Nevertheless, the treatment protocol used today has not changed since the 1980s.
In addition to not curing a large proportion of the children affected by medulloblastoma, current treatments impose severe, life-lasting side effects to the children who survive. And this is why the MBI works to connect private donors to great scientists.
The Opportunity
The role description and leadership profile are being developed and will be posted soon.
